Literature DB >> 23486236

Lactobacillus reuteri influences regrowth of mutans streptococci after full-mouth disinfection: a double-blind, randomised controlled trial.

N Romani Vestman1, P Hasslöf, M K Keller, E Granström, S Roos, S Twetman, C Stecksén-Blicks.   

Abstract

This study assessed whether the persistence of Lactobacillus reuteri DSM 17938 and ATCC PTA 5289 in saliva could delay the regrowth of mutans streptococci (MS) after a full-mouth disinfection with chlorhexidine (CHX). A randomised, double-blind, placebo-controlled study with a 6-week intervention period and 3- and 6-month follow-up was performed. 62 healthy subjects with moderate to high counts of MS were randomly assigned to a test group (n = 32) or a placebo group (n = 30). Before onset of the intervention, subjects received two sessions of professional cleaning, flossing, and application of CHX varnish and rinsed their mouth with a CHX solution between the sessions (2 days). Thereafter, the test group used probiotic lozenges (2/day) containing L. reuteri (DSM 17938 and ATCC PTA 5289; 1 × 10(8) CFU of each strain), and the placebo group used identical lozenges lacking the lactobacilli. Saliva samples were collected and cultured onto selective media, and isolates of L. reuteri as well as DNA directly extracted from saliva were tested by polymerase chain reaction (PCR) with specific primers. Presence of salivary MS was analysed with a chair-side test. L. reuteri was frequently detected by culture during the intervention period but in only 3 test group subjects at follow-ups. Regrowth of MS statistically significantly differed depending on the presence or absence of L. reuteri DSM 17938 detected by PCR. We conclude that cultivable L. reuteri strains may only sporadically be confirmed after termination of the intervention, but subjects with PCR-detected L. reuteri demonstrated slower regrowth of MS.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23486236     DOI: 10.1159/000347233

Source DB:  PubMed          Journal:  Caries Res        ISSN: 0008-6568            Impact factor:   4.056


  9 in total

1.  Lactobacillus reuteri Colonisation of Extremely Preterm Infants in a Randomised Placebo-Controlled Trial.

Authors:  Johanne E Spreckels; Erik Wejryd; Giovanna Marchini; Baldvin Jonsson; Dylan H de Vries; Maria C Jenmalm; Eva Landberg; Eva Sverremark-Ekström; Magalí Martí; Thomas Abrahamsson
Journal:  Microorganisms       Date:  2021-04-24

2.  Oral Microbiota Shift after 12-Week Supplementation with Lactobacillus reuteri DSM 17938 and PTA 5289; A Randomized Control Trial.

Authors:  Nelly Romani Vestman; Tsute Chen; Pernilla Lif Holgerson; Carina Öhman; Ingegerd Johansson
Journal:  PLoS One       Date:  2015-05-06       Impact factor: 3.240

3.  Effects of Lactobacillus reuteri supplementation on the gut microbiota in extremely preterm infants in a randomized placebo-controlled trial.

Authors:  Magalí Martí; Johanne E Spreckels; Purnika Damindi Ranasinghe; Erik Wejryd; Giovanna Marchini; Eva Sverremark-Ekström; Maria C Jenmalm; Thomas Abrahamsson
Journal:  Cell Rep Med       Date:  2021-02-22

4.  Effect of drops containing Lactobacillus reuteri (DSM 17938 and ATCC PTA 5289) on plaque acidogenicity and other caries-related variables in orthodontic patients.

Authors:  Sahal Alforaidi; Andrea Bresin; Naif Almosa; Anna Lehrkinder; Peter Lingström
Journal:  BMC Microbiol       Date:  2021-10-06       Impact factor: 3.605

5.  Clinical and microbiological effects of Lactobacillus reuteri probiotics in the treatment of chronic periodontitis: a randomized placebo-controlled study.

Authors:  Wim Teughels; Andaç Durukan; Onur Ozcelik; Martine Pauwels; Marc Quirynen; Mehmet Cenk Haytac
Journal:  J Clin Periodontol       Date:  2013-09-15       Impact factor: 8.728

6.  Effects of Lactobacillus salivarius-containing tablets on caries risk factors: a randomized open-label clinical trial.

Authors:  Tetsuyo Nishihara; Nao Suzuki; Masahiro Yoneda; Takao Hirofuji
Journal:  BMC Oral Health       Date:  2014-09-02       Impact factor: 2.757

Review 7.  Lactobacilli as Anti-biofilm Strategy in Oral Infectious Diseases: A Mini-Review.

Authors:  Barbara Giordani; Carola Parolin; Beatrice Vitali
Journal:  Front Med Technol       Date:  2021-10-20

8.  Flow cytometric analysis reveals culture condition dependent variations in phenotypic heterogeneity of Limosilactobacillus reuteri.

Authors:  Nikhil Seshagiri Rao; Ludwig Lundberg; Shuai Palmkron; Sebastian Håkansson; Björn Bergenståhl; Magnus Carlquist
Journal:  Sci Rep       Date:  2021-12-07       Impact factor: 4.379

9.  A protocol for characterization of extremely preterm infant gut microbiota in double-blind clinical trials.

Authors:  Magalí Martí; Johanne E Spreckels; Maria C Jenmalm; Thomas Abrahamsson
Journal:  STAR Protoc       Date:  2021-07-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.